Abstract
Information regarding the comparative efficacy and safety of first-generation treatments for Neurotrophic Tropomyosin Receptor Kinase (NTRK) fusion cancer is limited. Although cross-trial comparisons are subject to potential biases, a matching-adjusted indirect comparison (MAIC) can balance observed population characteristics to facilitate comparisons between trials. This study compared larotrectinib and entrectinib using MAIC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have